The effect of glucagon-like peptide 1 on cardiovascular risk (Q37980019)

26 August 2017

The effect of glucagon-like peptide 1 on cardiovascular risk (English)

1 reference

26 August 2017

1 reference

4

Tina Vilsbøll

1 reference

26 August 2017

Jens J Holst

3

0 references

author name string

Jacob Sivertsen

series ordinal

1

1 reference

26 August 2017

Jaya Rosenmeier

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

31 January 2012

1 reference

Nature Reviews Cardiology

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

209-222

1 reference

26 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrcardio.2011.211

26 August 2017

0 references

cites work

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Incidence of complications and mortality in a type 2 diabetes patient cohort study followed up from diagnosis in a primary healthcare centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

International Union of Pharmacology. XXXV. The glucagon receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Molecular cloning of a cDNA encoding for the GLP-1 receptor expressed in rat lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Identification and localization of glucagon-like peptide-1 and its receptor in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Heart-rate profile during exercise as a predictor of sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Myocardial reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Intentional weight loss and mortality among overweight individuals with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 binding to rat skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagonlike peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Characterization of high-affinity receptors for truncated glucagon-like peptide-1 in rat gastric glands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Renal effects of glucagon-like peptide in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: the Copenhagen City Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Glucagon-like peptide-1 drugs. Use of GLP-1 analogues needs great caution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.211

Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men.

31 March 2020

1 reference

12 December 2020

Ligand-specificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells

1 reference

12 December 2020

Abnormalities of the electrocardiogram during hypoglycaemia: the cause of the dead in bed syndrome?

1 reference

12 December 2020

GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery

1 reference

12 December 2020

Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats

1 reference

12 December 2020

Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats

1 reference

12 December 2020

10.1038/NRCARDIO.2011.211

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

0 references

1 reference